de following three-drug induction resulted in similar overall and progression-free survival, but increased toxicity, including more second primary malignancies [4]. For patients with standard-risk MM, we now suggest two years of lenalidomide maintenance

Key Takeaways

The 2022-23 Staff Performance Review Process is reviewing your work between March 1, 2022 – February 28, 2023.